HPP737

// HPP737

Overview

HPP737 is a novel, potent, and selective phosphodiesterase type 4 (PDE4) inhibitor in development for the treatment of psoriasis. In January 2026, vTv Therapeutics amended its licensing agreement with Newsoara Biopharma, granting Newsoara an exclusive worldwide license to develop and commercialize HPP737. Under the amended agreement, vTv received a $20 million upfront payment and is eligible to receive up to $52.5million in development milestones and up to $65 million in sales milestones, as well as tiered royalties on net sales. Newsoara has completed one Phase 3 study in China and is currently conducting a second Phase 3 study in support of a contemplated new drug application.

// HPP737

Clinical and Nonclinical Studies

vTv conducted one single- and two multiple-ascending-dose studies in healthy participants in the United States, all of which showed a favorable safety profile, with little to no gastrointestinal adverse events, such as nausea, vomiting, or diarrhea.

HPP737 has shown potent inhibition of interleukin-23 (IL-23) and tumor necrosis factor alpha (TNF-α) production in vitro and in vivo, as well as therapeutic activity in several animal models of inflammation. In addition, HPP737 showed target engagement ex vivo.

Mechanism of Action

PDE4 inhibitors increase intracellular cyclic adenosine monophosphate (AMP) levels, resulting in broad anti-inflammatory effects. However, the therapeutic potential of PDE4 inhibitors has historically been limited by dose-limiting adverse events, including nausea and emesis. Preclinical and clinical data to date suggest HPP737 may avoid some of the gastrointestinal side effects (e.g., nausea, vomiting, diarrhea) commonly associated with other PDE4 inhibitors.

Presentations & Posters

Links to the following presentations and posters, which are located on outside websites, are provided for informational purposes only and do not constitute the opinions or views of vTv Therapeutics

Burstein A., Wang S., Clark D., Kostura M., Dunn I. Pharmacokinetics and Pharmacodynamics of the Phosphodiesterase 4 (PDE4) inhibitor HPP737 Following Single-dose Administration in Healthy Subjects. Presented at the 6^th World Psoriasis and Psoriatic Arthritis Conference – Virtual, June 30, 2021.